Curesponse develops the cResponse™ test, a proprietary functional assessment that evaluates the efficacy of up to eight cancer therapies on a patient's biopsy while preserving the tumor's three-dimensional structure and microenvironment. This technology addresses the unpredictability of treatment responses by providing over 90% of patients with actionable insights for optimized cancer treatment plans.
Funding
$15.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Predicting patient response to cancer therapies remains a significant challenge, as individual tumors exhibit unique characteristics and react differently to treatment. While genomic sequencing can guide treatment selection, many patients do not benefit, leading to unpredictable outcomes and potentially ineffective treatment plans.
Solution
Curesponse offers the cResponse™ test, a functional assay that evaluates the efficacy of up to eight cancer therapies on a patient's tumor biopsy while preserving its three-dimensional structure and microenvironment. The test combines genomic profiling to prioritize potential therapies with functional testing to assess their effectiveness on the tumor cells. By maintaining the tumor microenvironment, cResponse™ emulates in-vivo conditions, enabling empirical analysis of treatment effectiveness with high accuracy. This approach provides actionable insights for optimized treatment plans, including chemotherapy, biologics, and immunotherapies.
Target Audience
The primary users are oncologists seeking to optimize treatment plans for cancer patients and improve prediction of treatment response.
Features
- Functional assessment of up to eight therapies, including chemotherapy, biologics, and immunotherapies
- Preservation of the tumor's 3D structure and microenvironment to mimic in-vivo conditions
- Combined genomic profiling to prioritize potential therapies
- High prediction accuracy for treatment efficacy and therapy resistance
- Actionable insights for optimized treatment plans
- Applicability to a broad range of solid tumor types